Triple-negative breast cancer trials in Austria

4 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  Where

  Innsbruck, Linz, Salzburg, Vienna, Wels

  Age

  18 years and over

  People

  1,530 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06393374 · EU 2023-504962-52-00
• Phase 2Taking people
  HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011

  Where

  Innsbruck

  Age

  18 years and over

  People

  60 worldwide

  Run by

  Abscint NV/SA

  See details and how to joinNCT06369831 · EU 2024-511419-22-00
• Phase 2/3Taking people
  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  Where

  Graz, Innsbruck, Salzburg, St. Poelten, Vienna

  Age

  18 years and over

  People

  600 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT06926868 · EU 2024-519871-24-00
• Phase 2Taking people
  Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases

  Where

  Vienna

  Age

  18 years and over

  People

  26 worldwide

  Run by

  Medical University Of Vienna

  See details and how to join2024-518819-19-00 · EU 2024-518819-19-00